Navigation Links
Jazz Pharmaceuticals Announces Development Timeline Updates
Date:6/11/2008

PALO ALTO, Calif., June 11 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced that timelines for two of its development programs have been delayed. In addition, the company will reduce its emphasis on early-stage research and development activities and implement a workforce reduction. Jazz Pharmaceuticals' sales and marketing activities will not be affected by these changes.

Clinical development will continue as previously disclosed for JZP-6, for which top-line results from the first of two Phase III clinical trials for the treatment of fibromyalgia syndrome are expected by the end of 2008. Jazz Pharmaceuticals recently announced completion of enrollment in this trial. Submission of a New Drug Application for JZP-6 is targeted for the fourth quarter of 2009. As previously disclosed, the ongoing Phase II trial of JZP-8, in development for the treatment of recurrent acute repetitive seizures, is also expected to be completed during 2008.

The company plans to complete additional pre-clinical activities prior to initiation of the Phase III program for JZP-7, its product candidate for the treatment of restless legs syndrome. As a result, the start of the Phase III program for JZP-7 will be delayed. The Phase II clinical development of JZP-4, Jazz Pharmaceuticals' product candidate for the chronic treatment of epilepsy and bipolar disorder, will be delayed to allow further formulation development work to be completed. The Phase II trial for JZP-4 and the Phase III trials for JZP-7 and JZP-8 will proceed in 2009 with additional financing or development partners for the company.

"Reducing our overall R&D spending commitments and streamlining our administrative operations gives us additional f
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... Celebrating a decade of philanthropy in ... the awarding of $1,070,000 in grants to 20 New ... of the Foundation’s 1,000th grant. , “The Horizon Foundation ... of supporting community-based organizations that are working to improve ... the Garden State,” said Robert A. Marino, Horizon Blue ...
(Date:7/23/2014)... study supports a growing body of research suggesting ... hormones in treating postmenopausal breast cancer, with fewer ... with standard anti-hormone therapies. The study will be ... journal Reproductive Biology and Endocrinology . , ... in women in the United States. Approximately 70% ...
(Date:7/23/2014)... Global Cardio Care, Inc., a management ... (EECP), is celebrating the 100th birthday of Albert ... health center. , Weber has been plagued with ... EECP therapy since 1999, he no longer suffers from ... Global Cardio Care, introduced the Sara Soulati Health ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 The voice on the ... call that brought the news he was infected with the human ... a little bit and next thing you know I was on ... , Yet the message was hopeful when the recording ended less ... of you . . . because it is just God ...
(Date:7/23/2014)... -- For patients infected with both HIV and hepatitis ... viruses, a small study suggests. Researchers said doctors ... people with the two diseases. "The findings ... important role in the management of individuals with [hepatitis ... Sherman, a professor of medicine at the University of ...
Breaking Medicine News(10 mins):Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 2Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 3Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 4Health News:The Horizon Foundation for New Jersey Awards More than $1 million in Grants to 20 Non-profit Organizations 5Health News:Hormones after breast cancer: Not fuel for the fire after all? 2Health News:Hormones after breast cancer: Not fuel for the fire after all? 3Health News:Hormones after breast cancer: Not fuel for the fire after all? 4Health News:Hormones after breast cancer: Not fuel for the fire after all? 5Health News:Global Cardio Care Celebrates EECP Patient’s 100th Birthday 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 2Health News:HIV clinic-based audio project emphasizes the power of patient voices 3Health News:HIV Meds May Also Help Control Hepatitis C, Study Finds 2
... finds children with sickle cell disease are more likely to ... if they live in households where people smoke.// ,Study ... harm the health of nonsmokers. It is found that exposure ... to a vast array of problems. ,In sickle ...
... show obese men with prostate cancer are at a higher ... recurrence than men of normal weight.// ,The first ... San Diego sampled nearly 3,200 prostate cancer patients. In this ... defined as having a body mass index higher than 30. ...
... valacyclovir may significantly reduce the spread of the genital ... each case, one partner was diagnosed with //type 2 ... Type 2 herpes causes a chronic genital viral infection ... herpes were given either 500 milligrams of valacyclovir once ...
... New research proves drug-coated stents effectively combat death, heart ... a closer look at the effects of drug-coated stents ... 500 patients with previously untreated blocked arteries who were ... comparable blockages were treated with bare metal stents. ...
... million service men and women before and after the Air ... rate of suicide seen among Air Force personnel. // ... for black and white males ages 24 to 35, between ... are to provide support for soldiers facing mental health or ...
... simplex virus is a common eye disease affecting people worldwide. ... cases are identified // annually. The disease is caused by ... get the infection will have repeat infections. The recurrence rate ... five years, and 67 percent within seven years. ...
Cached Medicine News:Health News:Prostate Cancer in Obese Men 2
(Date:7/23/2014)... 23, 2014  Researchers from the North American Menopause ... elevates calcium levels too high, 1 putting women ... Women close to menopause are commonly told ... prevent diseases such as osteoporosis, to which they are ... determine how much calcium they typically get through their ...
(Date:7/23/2014)... 23, 2014  Mevesi Inc. would like to ... integration provides pharmacies with the ability to send ... patients. Mevesi,s solutions provide an ... to define target marketing campaigns. This coupled with ... within the Digital Marketing, Population Management, and Pharmacy ...
(Date:7/23/2014)... 2014 Global healthcare company GSK ... currency headwinds, increased price competition and supply disruptions to ... Witty points out that the company is very much ... to be confident about long-term prospects as well as ... CFO Simon Dingemans adds that the ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
... , , Trial taking place ... Ky., July 24 Michael (Mike) Jones has become the world,s first ... infusion on July 17 marks the world,s first phase-one FDA-approved clinical trial ... is being conducted by a team of University of Louisville physicians at ...
... , WISCONSIN RAPIDS, Wis., July 23 ... Riverview became the first medical facility in the world to ... within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview ... FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, ...
Cached Medicine Technology:World's First Cardiac Adult Stem Cell Patient Receives Infusion 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
...
Small diameter high tech flexoscopes...
... cervical plate system features an advanced design ... needs. Trinica system gives surgeons the flexibility ... unique anatomy. Flexibility is built-in to every ... and the innovative Secure-Twist anti-migration system to ...
... intended for supportive stabilization of the ... The device utilizes bi-cortical fixation for ... enhanced through dynamic screw holes and ... level interbody fusion. Anterior cervical corpectomy. ...
Medicine Products: